Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: A validation using antipsychotic and glutamatergic agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 1, 2013, Pages 151-160

  Doyle, O M ^a   De Simoni, S ^a   Schwarz, A J ^b,c   Brittain, C ^b   O'Daly, O G ^a   Williams, S C R ^a   Mehta, M A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLUTAMIC ACID DERIVATIVE; KETAMINE; LAMOTRIGINE; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG HALF LIFE; FRONTAL LOBE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROBABILITY; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SUBGENUAL PREFRONTAL CORTEX; THALAMUS NUCLEUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG MONITORING; EXCITATORY AMINO ACID AGENTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; NORMAL DISTRIBUTION; PREDICTIVE VALUE OF TESTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84875475490     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201665     Document Type: Article

References (45)

1. Absalom AR, Lee M, Menon DK, Sharar SR, De Smet T, Halliday J, Ogden M, Corlett P, Honey GD, and Fletcher PC (2007) Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers. Br J Anaesth 98:615-623.
2. Adams B and Moghaddam B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554.
3. Aghajanian GK and Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312.
4. Agid Y, Buzsáki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, Grace A, Lambert JJ, Manji H, and Mayberg H, et al. (2007) How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 6:189-201.
5. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, and Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276.
6. Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, and Day M (2011) Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther 336:709-715.
7. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, and Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42:535-541.
8. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, Stephenson S, Williams SC, and Mehta MA (2013) Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage 64:75-90.
9. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, and Dursun SM (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmacomagnetic resonance imaging study. Arch Gen Psychiatry 65:154-164.
10. Didriksen M, Skarsfeldt T, and Arnt J (2007) Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 193:225-233.
11. Duncan GE, Leipzig JN, Mailman RB, and Lieberman JA (1998a) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812:65-75.
12. Duncan GE, Miyamoto S, Leipzig JN, and Lieberman JA (2000) Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 293:8-14.
13. Duncan GE, Moy SS, Knapp DJ, Mueller RA, and Breese GR (1998b) Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 787:181-190.
14. Fang J, Bourin M, and Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147-151.
15. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, and Olney JW (1995) Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38:788-796.
16. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, and Ericsson B (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15(1, Suppl 1) 19S-23S.
17. Freeman AS and Bunney BS (1984) The effects of phencyclidine and Nallylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 104:287-293.
18. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, and Bifone A (2008) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 33:1690-1703.
19. Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, Grier MD, Avison M, Conn PJ, and Gore JC (2010) Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 168:209-218.
20. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, and Jonkman JH (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268.
21. Kapur S and Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors- implications for models of schizophrenia. Mol Psychiatry 7:837-844.
22. Krimer LS, Muly EC, 3rd, Williams GV, and Goldman-Rakic PS (1998) Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1:286-289.
23. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB, Jr, Vegso S, and Heninger GR, et al. (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145:193-204.
24. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
25. Långsjö JW, Salmi E, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, Viljanen T, Kurki T, and Silvanto M, et al. (2004) Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 100:1065-1071.
26. Large CH (2007) Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 21:283-301.
27. Large CH, Webster EL, and Goff DC (2005) The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181:415-436.
28. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, and Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706.
29. Madsen MT (1992) A simplified formulation of the gamma variate function. Phys Med Biol 37:1597-1600 DOI: 10.1088/0031-9155/37/7/010.
30. Mantere T, Tupala E, Hall H, Särkioja T, Räsänen P, Bergström K, Callaway J, and Tiihonen J (2002) Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a wholehemisphere autoradiography study. Am J Psychiatry 159:599-606.
31. Marquand A, Howard M, Brammer M, Chu C, Coen S, and Mourão-Miranda J (2010) Quantitative prediction of subjective pain intensity from whole-brain fMRI data using Gaussian processes. Neuroimage 49:2178-2189.
32. Meltzer HY, Horiguchi M, and Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213:289-305.
33. Mirjana C, Baviera M, Invernizzi RW, and Balducci C (2004) The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29:1637-1647.
34. Moghaddam B, Adams B, Verma A, and Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
35. Morgan CJ, Mofeez A, Brandner B, Bromley L, and Curran HV (2004) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29:208-218.
36. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, and Farde L (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875.
37. Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, and Kahn RS (2009) Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. Int J Neuropsychopharmacol 12: 823-832.
38. Rasmussen CE, Williams CKI (2006) Gaussian Processes for Machine Learning, MIT Press, Cambridge, MA.
39. Schmidt CJ and Fadayel GM (1996) Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 277:1541-1549.
40. Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, Krystal JH, Nutt D, and Barker GJ (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry 17:664-665.
41. Tauscher J, Hussain T, Agid O, Verhoeff NPLG, Wilson AA, Houle S, Remington G, Zipursky RB, and Kapur S (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 161:1620-1625.
42. Varnäs K, Halldin C, and Hall H (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22:246-260.
43. Varty GB, Bakshi VP, and Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311-321.
44. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, and Angst J (1997) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9-24.
45. Wong EC, Buxton RB, and Frank LR (1997) Implementation of quantitative perfusion imaging techniques for functional brain mapping using pulsed arterial spin labeling. NMR Biomed 10:237-249.